Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Jazz Pharmaceuticals plc

SG&A Costs: Jazz vs. Summit - A Decade of Divergence

__timestampJazz Pharmaceuticals plcSummit Therapeutics Inc.
Wednesday, January 1, 20144061140006795238
Thursday, January 1, 20154491190007454247
Friday, January 1, 201650289200010345862
Sunday, January 1, 201754415600016984203
Monday, January 1, 201868353000016187290
Tuesday, January 1, 20197369420009299233.54
Wednesday, January 1, 202085423300019232000
Friday, January 1, 2021145168300023611000
Saturday, January 1, 2022141696700026700000
Sunday, January 1, 2023134310500028215000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Companies: SG&A Expenses in the Biopharmaceutical Sector

In the competitive world of biopharmaceuticals, managing operational costs is crucial. Over the past decade, Jazz Pharmaceuticals plc and Summit Therapeutics Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals, a leader in the field, has seen its SG&A costs rise by approximately 230% from 2014 to 2023, peaking in 2021. This increase reflects their aggressive expansion and investment in new therapies. In contrast, Summit Therapeutics, a smaller player, has maintained a more modest growth in SG&A expenses, with a 315% increase over the same period, indicating a strategic focus on lean operations. These trends highlight the diverse strategies within the industry, where larger firms invest heavily in growth, while smaller companies prioritize efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025